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Abstract
Prepulse inhibition (PPI) of acoustic startle response is impaired in patients with schizophrenia and in animals acutely
treated with dopamine agonists and NMDA antagonists. In this study, we investigated the time course of PPI disruption
induced by repeated amphetamine, quinpirole, phencyclidine (PCP), and dizocilpine (MK-801) treatment. We focused
on how PPI disruption development was influenced by drug administration regimens, comparing a constant versus an escalating dosing regimen. Male Sprague–Dawley rats were repeatedly treated with amphetamine (1.25–5.0 mg/kg, or constant 5.0 mg/kg, sc), PCP (0.50–2.0 mg/kg, or constant 0.5, 1.0 or 2.0 mg/kg, sc), quinpirole (0.03–0.12 mg/kg, or constant
0.12 mg/kg, sc), MK-801 (0.025–0.10 mg/kg, or constant 0.10 mg/kg, sc) or vehicle (saline) and tested for PPI once daily
for 6 consecutive days. When amphetamine 5.0 mg/kg or quinpirole 0.12 mg/kg was administrated on a constant dosing schedule, both drugs disrupted PPI upon acute administration, but had no effect after repeated treatment and testing
(days 2–5). However, when amphetamine 5.0 mg/kg or quinpirole 0.12 mg/kg was preceded by two lower doses in an escalating dosing regimen, both drugs still disrupted PPI on days 5 and 6 when the constant amphetamine and quinpirole had
no effect. For PCP and MK-801, repeated treatment under both regimens produced a stable and persistent disruption of
PPI. Startle magnitude increased progressively and dose-dependently under both regimens for all drugs except for quinpirole, which caused a decrease. These results suggest that the drug dosing schedule, rather than the absolute amount of
drug that an animal receives, has a greater impact on the development of PPI-disruptive effect of dopamine agonists than
NMDA antagonists. Thus, in order to mimic the emerging process of PPI deficit with dopamine agonists, an escalating
dosing regimen should be used.
Keywords: prepulse inhibition of acoustic startle, repeated amphetamine treatment, repeated phencyclidine treatment,
quinpirole, dizocilpine (MK-801), sensitization effect, tolerance effect
1. Introduction

One issue with psychomotor sensitization and stereotypy as
behavioral indices of schizophrenic symptoms is that they are not
essential features of schizophrenia and do not seem to capture the
emotional, cognitive, and perceptual disturbances that characterize schizophrenic disorders. Other behavioral abnormalities induced by repeated psychotomimetic drug treatment, such as disruption of prepulse inhibition (PPI) of acoustic startle response
(ASR), may provide a better model for drug-induced psychosis or
even idiopathic schizophrenia (Braff et al., 2001). PPI refers to the
phenomenon of a reduction in the startle magnitude when the
startling stimulus is preceded by a low-intensity prepulse. It has
been widely used as a translational model of schizophrenia (Geyer
and Braff, 1987; Swerdlow et al., 2008) which measures the sensorimotor gating ability, a pre-attentive information processing
mechanism that is putatively disrupted in patients with schizophrenia and is thought to contribute to their sensory flooding
and cognitive fragmentation (Braff and Geyer, 1990; Swerdlow et
al., 2000). Animals treated with acute amphetamine, quinpirole
(a D2/3 agonist), PCP or MK-801 (a NMDA antagonist) also exhibit PPI deficits (Culm and Hammer, 2004; Mansbach and Geyer,

Clinical studies suggest that repeated intermittent exposure to
dopamine agonists or releasers such as amphetamine and cocaine and non-competitive NMDA receptor antagonists such as
ketamine and phencyclidine (PCP) can induce psychotic symptoms very similar to those observed in patients with schizophrenia (Bell, 1965; Janowsky and Risch, 1979; Javitt and Zukin, 1991).
These drug-induced symptoms often emerge gradually and are
progressively worsened with repeated drug exposure over a period
of time (Ellinwood et al., 1973; Griffith et al., 1972). They are most
often observed following a chronic escalating pattern of drug exposure (Angrist, 1994; Simon et al., 2002). This temporal feature
is often modeled in animals by repeatedly treating them with psychotomimetic drugs and then examining the progressive increase
in the sensitivity of an animal’s response to the psychotogenic
properties of drugs (Martinez et al., 2005; Nestler, 2001; Robinson
and Becker, 1986), most noticeably, behavioral sensitization in the
forms of locomotor activity and stereotypy (Segal et al., 1981; Segal
and Mandell, 1974).
509

510

Li, He, & Chen in Pharmacology Biochemistry and Behavior 99 (2011)

1989; Mansbach et al., 1988; Schwabe et al., 2005). However, it is
not clear whether repeated treatment with these drugs induces a
persistent disruption of PPI. So far, the evidence is inconclusive
(Geyer et al., 2001). Sensitization (a progressive increase in PPIdisruption), tolerance (a progressive decrease in PPI-disruption),
and no change in PPI have all been reported (Culm and Hammer,
2004; Mansbach et al., 1988; Martin-Iverson, 1999; Schulz et al.,
2001; Schwabe et al., 2005).
The paradigm used to administer psychotomimetic drugs is
an extremely important variable to consider in evaluating druginduced behavioral sensitization phenomena (Fletcher et al.,
2005; Robinson and Becker, 1986; Tenn et al., 2005). The abovementioned conflicting reports may be due to differences in the
treatment paradigms used, including drug doses, number of
drug administrations, routes and treatment schedule, as well
as the PPI testing schedule. In the present study, we sought to
explore under what condition repeated treatment of amphetamine, quinpirole, PCP and MK-801 could produce a persistent
disruption of PPI. We examined two dosing regimens. After habituation and baseline saline PPI tests were conducted, rats were
treated under either a constant dosing regimen or an escalating
dosing regimen for 6 consecutive days and their PPIs were tested
daily. For amphetamine and quinpirole, we found that the constant dosing regimen produced an acute disruption of PPI. But
with repeated treatment and testing, both drugs no longer disrupted PPI. In contrast, amphetamine and quinpirole administrated in an escalating dosing regimen produced PPI disruption
even after repeated treatment and testing. For PCP and MK801, both treatment regimens produced a stable and persistent
disruption of PPI at the dose range tested in this study (0.50–
2.0 mg/kg for PCP and 0.025–0.10 mg/kg for MK-801). Our results thus emphasize the importance of drug administration paradigms for different psychotomimetic drugs, rather than the
amount of drugs, in producing different patterns of psychopharmacological effects on PPI. They also suggest that for dopamine
agonists or indirect agonists, an escalating dosing regimen may
be more appropriate in inducing behavioral changes in rats with
close resemblance to symptoms of schizophrenia.
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats (250–275 g upon arrival,
Charles River, Portage, MI) were housed two per cage, in
48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages
under 12-h light/dark conditions (light on between 6:00 am and
6:00 pm). Room temperature was maintained at 22° ± 1° with a
relative humidity of 40–60%. Food and water was available ad libitum. Animals were allowed at least 1 week of habituation to the
animal facility before being used in experiments. All procedures
were approved by the animal care committee at the University of
Nebraska-Lincoln.
2.2. Prepulse inhibition of acoustic startle reflex apparatus
The prepulse inhibition test was performed using six Startle
Monitor Systems (Kinder Scientific, Julian, CA). Each system,
controlled by a PC, was housed in a compact sound attenuation
cabinet (36 cm wide × 28 cm deep × 50 cm high). A speaker (diameter: 11 cm) mounted on the cabinet’s ceiling was used to generate acoustic stimuli (70 dB–120 dB). The startle response was
measured by a piezoelectric sensing platform on the floor, which
was calibrated daily. During testing, rats were placed in a rectangular box made of transparent Plexiglas (19 cm wide × 9.8 cm
deep × 14.6 high) with an adjustable ceiling positioned atop
the box, providing only limited restraint while prohibiting
ambulation.

2.3. Drugs
The injection solutions of d-amphetamine sulfate (AMPH, SigmaAldrich, St. Louis, MO), quinpirole (QUI, Sigma-Aldrich, St. Louis,
MO), (+)-MK-801 Hydrogen Maleate (a gift from NIMH Chemical Synthesis and Drug Supply Program) and PCP hydrochloride
(a gift from NIDA Chemical Synthesis and Drug Supply Program)
were obtained by mixing drugs with 0.9% saline. All injections
were administrated subcutaneously at a volume of 1 ml/kg.
2.4. Experiment 1: Effects of repeated amphetamine (1.25–
5.0) or PCP (0.5–2.0) treatment on an escalating dose regimen or a constant dose regimen on prepulse inhibition
The entire experiment consisted of the following three phases,
each separated by 1 day.
2.4.1. Phase 1: Handling and PPI habituation (2 days)
Rats (n = 60) were first handled individually for 2 days for approximately 2 min each day to minimize stress during behavioral
testing. On the first handling day, the rats were acclimated to the
prepulse inhibition apparatus for 10 min. On the second handling day, the rats were also habituated to the PPI test procedure,
which was adapted from Culm and Hammer (2004). The PPI session lasted approximately 18 min and began with a 5 minute period of 70 dB background noise (which continued throughout
the duration of the session) followed by four different trial types:
PULSE ALONE trials and three types of PREPULSE + PULSE trials, which consisted of a 20 ms 73, 76, or 82 dB prepulse (3, 6, and
12 dB above background) followed 100 ms later by a 120 dB pulse.
Each session was divided into 4 blocks. Blocks 1 and 4 were identical, each consisting of 4 PULSE ALONE trials. Blocks 2 and 3
were also identical and each consisted of 8 PULSE ALONE trials and 5 of each PREPULSE + PULSE trial type. A total of 54
trials were presented during each test session. Trials within each
block were presented in a pseudorandom order and were separated by a variable inter-trial interval averaging 15 s (ranging
from 9 to 21 s). Startle magnitude was defined as the maximum
force (measured in Newtons) applied by the rat to the startle apparatus recorded over a period of 100 ms beginning at the onset of the pulse stimulus. Startle responses from testing blocks 2
and 3 were used to calculate percent prepulse inhibition (%PPI)
for each acoustic prepulse trial type:
%PPI = 100 –

startle response to PREPULSE + PULSE trials
× 100]
[(average
average startle response to PULSE ALONE trials )

2.4.2. Phase 2: PPI testing under vehicle (1 day)
One day after the second habituation day, rats were injected subcutaneously with saline and tested for PPI 10 min after injection.
The averaged %PPI at three prepulse levels (73, 76, and 82 dB) on
this day was used to create matched groups such that all groups
had comparable baseline PPI performance before the drug tests.
2.4.3. Phase 3: Repeated PPI testing under drug (6 days)
Five groups (n = 12/group) were formed on the basis of their PPI
on the saline day: VEH (saline, sc), AMPH-constant (5.0 mg/
kg, sc), AMPH-escalating (1.25–5.0 mg/kg, sc), PCP-constant
(2.0 mg/kg, sc), PCP-escalating (0.5–2.0 mg/kg, sc). During each
daily test, rats were injected with either saline, AMPH or PCP
10 min prior to being placed into the PPI boxes. Table 1 depicts
the daily injection schedule.
2.5. Experiment 2: Effects of repeated PCP (0.5 or 1.0 mg/kg)
treatment on a constant dose regimen on prepulse inhibition
Results from Experiment 1 showed that PCP (2.0 mg/kg) administrated under the constant dosing schedule maintained its
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Table 1. Groups and drug treatment for Experiment 1 (All drugs were administrated subcutaneously at a volume of 1 ml/kg).
Group

N

D1

D2

D3

D4

D5

D6

Vehicle
AMPH constant
AMPH escalating
PCP constant
PCP escalating

12
12
12
12
12

SAL
5.0
1.25
2.0
0.5

SAL
5.0
1.25
2.0
0.5

SAL
5.0
2.5
2.0
1.0

SAL
5.0
2.5
2.0
1.0

SAL
5.0
5.0
2.0
2.0

SAL
5.0
5.0
2.0
2.0

disruption. Experiment 2 further examined this issue using two
lower doses of PCP (0.5 and 1.0 mg/kg) and also addressed the potential floor effect (PCP at 2.0 mg/kg already caused a maximal
PPI disruption, leaving no room to show a sensitization effect).
Two lower doses of PCP (0.5 and 1.0 mg/kg) were used. The basic
procedure was identical to that of Experiment 1. Based on the PPI
performance on the saline day, 36 rats were matched and assigned
to three groups (n = 12/group): VEH (saline), PCP 0.5 mg/kg and
PCP 1.0 mg/kg, and their PPIs were tested for 6 days.
2.6. Experiment 3: Effects of repeated quinpirole (0.03–0.12)
or MK-801 (0.025–0.1) treatment on an escalating dose regimen or a constant dose regimen on prepulse inhibition
Quinpirole and MK-801 are two drugs that are often used in the
study of animal models of schizophrenia. Like amphetamine and
PCP, both drugs affect dopamine and NMDA-mediated neurotransmission and acutely disrupt PPI, but their repeated effects on
PPI are less clear. This experiment investigated the effects of repeated administration of quinpirole and MK-801 under the two
dosing schedules on PPI. We were interested in whether the regimen effect with amphetamine and PCP could also be found
with quinpirole and MK-801. The basic procedure was identical
to that of Experiment 1. Sixty rats were matched and assigned to
five groups (n = 12/group): VEH (saline), QUI-constant (0.12 mg/
kg, sc), QUI-escalating (0.03–0.12 mg/kg, sc), MK-801-constant
(0.10 mg/kg, sc), MK-801-escalating (0.025–0.10 mg/kg, sc). PPI
was tested for 6 days. During each daily test, rats were injected
with either saline or one of the drugs 10 min prior to being placed
into the PPI boxes. Table 2 depicts the daily injection schedule.
2.7. Statistical analysis
Percent PPI data for the 6 drug days were presented separately
for three prepulse intensities (e.g. 73, 76 and 82 dB). The magnitude of the acoustic startle reflex (ASR) was calculated as the average response on the PULSE ALONE trials, excluding the first
and last blocks of 4 PULSE ALONE trials. Percent PPI and ASR
data from the drug test period were first analyzed using SPSS
(v19) repeated measures ANOVAs with drug treatment (i.e. vehicle, constant or escalating) as a between-subjects factor and
test day (i.e. 6) as a within-subjects factor. For PPI data, another
within-subjects factor (i.e. 3 prepulse levels) was also included
in the analysis. If necessary, one-way ANOVAs followed by post
hoc LSD tests were used to identify between-group differences
on specific days, and paired-samples t tests were used to identify the temporal changes of treatment effects from day 1 to day
6. Data for each drug (e.g. AMPH and PCP) were analyzed separately because we were primarily interested in the effects of
Table 2. Groups and drug treatment for Experiment 3 (All drugs were
administrated subcutaneously at a volume of 1 ml/kg).
Group

No. Drug treatment (Days 1–6)

Vehicle
QUI constant
QUI escalating
MK-801 constant
MK-801 escalating

12
12
12
12
12

SAL
0.12
0.03
0.10
0.025

SAL
0.12
0.03
0.10
0.025

SAL
0.12
0.06
0.10
0.05

SAL
0.12
0.06
0.10
0.05

SAL
0.12
0.12
0.10
0.10

SAL
0.12
0.12
0.10
0.10
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dosing regimen and less interested in differences between drugs.
For all analyses, P < 0.05 was considered statistically significant.
3. Results
3.1. Experiment 1: Effects of repeated amphetamine (1.25–
5.0) or PCP (0.5–2.0) treatment on an escalating dose regimen or a constant dose regimen on prepulse inhibition
Due to equipment malfunction on the last drug test day, data
for 12 rats were lost (1 vehicle, 3 AMPH-constant, 3 AMPH-escalating, 2 PCP-constant and 3 PCP-escalating rats). The following analysis was based on the data from the remaining 48 rats
(n = 9–11/group).
3.1.1. PPI
As expected, there was no group difference on the averaged percent PPI on the saline day (F(4, 55) = 0.08, P = 0.988, data not
shown). For amphetamine, analysis of PPI data from the 6 drug
test days revealed a main effect of treatment (F(2, 26) = 4.249,
P = 0.025), prepulse level (F(2, 52) = 366.66, P < 0.001) and a
significant treatment × test day interaction (F(10, 130) = 3.472,
P < 0.001). These results suggest that amphetamine disrupted
PPI and the disruption varied in different treatment schedules
and across the test days.
At all three prepulse intensity levels (Figure 1A, B and C),
one-way ANOVA followed by LSD post hoc tests revealed that
the AMPH-constant group had significantly lower PPIs than
the other two groups only on day 1 (all Ps < 0.003), indicating
an acute PPI-disruptive effect of AMPH at 5.0 mg/kg. In contrast, the AMPH-escalating group had significantly lower PPIs
than the vehicle group primarily on day 5 and 6 at the 76 dB
(P = 0.014, and 0.050) and 82 dB levels (P = 0.009 and 0.008). It
also had a significantly lower PPI than the vehicle group at the
76 dB level on day 1 (P = 0.011).
When PPIs on day 6 of drug testing were compared to those on
day 1, the vehicle and AMPH-escalating groups did not show any
significant change in PPI at all three prepulse levels (all Ps > 0.105).
In contrast, the AMPH-constant group had significantly higher
PPIs on day 6 than on day 1 at the 73 dB (P = 0.007) and 82 dB levels (P = 0.033), indicating that repeated AMPH treatment at this
constant dose induced a tolerance-like effect on PPI disruption.
For PCP, repeated measures ANOVA showed a main effect of treatment (F(2, 27) = 54.987, P < 0.001) and prepulse
level (F(2, 54) = 359.939, P < 0.001). There was also a significant
treatment × test day interaction (F(10, 135) = 1.932, P = 0.046),
and a significant treatment × prepulse level interaction (F(4,
54) = 11.211, P < 0.001). These results suggest that the disruptive
effect of PCP on PPI varied under different treatment schedules
and differed at different prepulse levels on different test days.
At the 73 and 76 dB prepulse intensity levels (Figure 2A and
B), one-way ANOVA followed by LSD post hoc tests revealed
that both PCP groups had significantly lower PPIs than the vehicle group on every test day (all Ps < 0.035) except on day 3 when
the difference between the PCP-escalating group and the vehicle
group did not reach the significant level (P = 0.059) at the 73 dB
level. In addition, the PCP-constant group also had a significantly
lower PPI than the PCP-escalating group on day 3 at the 73 dB prepulse level (P = 0.010) and on day 4 at the 76 dB prepulse level
(P = 0.011). Similarly, at the 82 dB prepulse intensity level (Figure 2C), both PCP groups had significantly lower PPIs than the
vehicle group on all 6 test days (all Ps < 0.001). In addition, the
PCP-constant group also had significantly lower PPIs than the
PCP-escalating group on day 3 (P < 0.008) and day 4 (P < 0.044).
Comparing day 1 versus day 6, neither the PCP-constant nor
the PCP-escalating group showed any significant change in PPI
at all three prepulse levels (all Ps > 0.176), indicating that repeated PCP treatment under either treatment schedule produced a persistent PPI disruption.
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Figure 1. Effects of repeated administration of saline (VEH), constant
amphetamine (5.0 mg/kg daily), or escalating amphetamine (1.25–
5.0 mg/kg) for 6 consecutive days on prepulse inhibition (PPI) at the
73 dB (A), 76 dB (B), and 82 dB (C) prepulse levels. * P < 0.05 significantly different from the VEH group; # P < 0.05 significantly different
between the two amphetamine groups; $ P < 0.05 significantly different
between day 1 and day 6.

Figure 2. Effects of repeated administration of saline (VEH), constant
PCP (2.0 mg/kg daily), or escalating PCP (0.5–2.0 mg/kg) for 6 consecutive days on prepulse inhibition (PPI) at the 73 dB (A), 76 dB (B) and
82 dB (C) prepulse levels. * P < 0.05 significantly different from the VEH
group; # P < 0.05 significantly different between the two PCP groups.

3.1.2. Acoustic startle response (ASR)
For AMPH (Figure 3A), both AMPH regimens progressively
enhanced startle amplitude over the treatment period. Repeated measures ANOVAs showed a main effect of test day (F(5,
130) = 7.520, P < 0.001) and a significant treatment × test day interaction (F(10, 130) = 5.049, P < 0.001). One-way ANOVAs followed by LSD post hoc test on each test day showed that the
AMPH-constant group had significantly higher startle amplitude than the vehicle group on days 3, 4, 5 and 6 (all Ps < 0.043

vs. vehicle) (Figure 3A). The AMPH-escalating group had significantly higher startle amplitude than the vehicle group only
on day 5 (P = 0.010). For PCP (Figure 3B), repeated measures
ANOVAs showed a main effect of treatment (F(2, 27) = 5.737,
P = 0.008) and a significant treatment × test day interaction
(F(10, 135) = 2.364, P = 0.013). One-way ANOVAs showed that
both PCP groups significantly enhanced startle amplitude on all
6 test days (all Ps < 0.043 vs. vehicle) with the exception of the
PCP-constant group on day 1 (P = 0.154).

Prepulse inhibition disruption induced by dopamine agonists and NMDA antagonists
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Figure 3. Effects of repeated administration of saline (VEH), constant
amphetamine (5.0 mg/kg daily), escalating amphetamine (1.25–5.0 mg/
kg) (A), constant PCP (2.0 mg/kg daily), or escalating PCP (0.5–2.0 mg/
kg) for 6 consecutive days (B) on startle reactivity (e.g. startle responses
on 120 dB white noise trials). Startle magnitude (mean ± SEM) was calculated as the average response on the PULSE ALONE trials, excluding
the first and last block of 4 PULSE ALONE trials. * P < 0.05 significantly
different from the VEH group.

3.2. Experiment 2: Effects of repeated PCP (0.5 or 1.0 mg/
kg) treatment on a constant dose regimen on prepulse
inhibition
Due to equipment malfunction on the 5th drug test day, data for
4 rats were lost (2 vehicle rats and 2 PCP 0.5 mg/kg rats). The
following analysis was based on the data from the remaining 32
rats (n = 10–12/group).
3.2.1. PPI
As expected, there was no group difference on the averaged percent
PPI on the saline day (F(2, 33) = 0.074, P = 0.929). Analysis of PPI
data from the 6 drug test days revealed a main effect of treatment
(F(2, 29) = 11.853, P < 0.001) and prepulse level (F(2, 58) = 328.635,
P < 0.001), but no main effect of test day (F(5, 145) = 0.832,
P = 0.529), nor a significant treatment × test day interaction (F(10,
145) = 1.70, P = 0.086). In addition, the treatment × prepulse level
interaction was also not significant (F(4, 58) = 2.518, P = 0.051).
Like the effect of PCP administered in the constant dosing regimen
seen in Experiment 1, PCP at 0.5 and 1.0 mg/kg produced a persistent disruption of PPI across the test days.
At the 73 dB prepulse intensity level (Figure 4A), one-way
ANOVA followed by LSD post hoc tests revealed that the PCP
1.0 group had significantly lower PPIs than the vehicle group

Figure 4. Effects of repeated administration of saline (VEH), PCP
(0.5 mg/kg) or PCP (1.0 mg/kg) daily for 6 consecutive days on prepulse
inhibition (PPI) at the 73 dB (A), 76 dB (B) and 82 dB (C) prepulse levels.
* P < 0.05 significantly different from the VEH group; # P < 0.05 significantly different between the two PCP groups.

on day 1 (P = 0.009) and day 5 (P = 0.036), whereas the PCP 0.5
group had significantly lower PPI only on day 6 (P = 0.020). At
the 76 dB prepulse intensity level (Figure 4B), both PCP groups
had significantly lower PPIs than the vehicle group on every test
day (all Ps < 0.036) except on day 5 when the difference between
the PCP 0.5 and vehicle group was only marginally significant
(P = 0.051). At the 82 dB prepulse intensity level (Figure 4B), the
PCP 1.0 group had significantly lower PPIs than the vehicle group
on every test day (all Ps < 0.048), whereas the PCP 0.5 group had
significantly lower PPIs on days 1, 3, and 4 (all Ps < 0.042).
The vehicle and PCP 1.0 groups did not show any significant
change in PPI performance at all three prepulse levels from day 1
to day 6 (all Ps > 0.713). The only significant change noticed was in
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Figure 5. Effects of repeated administration of saline (VEH), PCP (0.5 mg/
kg), or PCP (1.0 mg/kg) for 6 consecutive days on startle reactivity.

the PCP 0.5 group which had significantly lower PPI at the 73 dB
level on day 6 than on day 1 (P = 0.026). Collectively, these data
indicate that repeated PCP treatment under the constant dosing
schedules produced a stable and persistent PPI disruption.
3.2.2. Acoustic startle response (ASR)
There was a main effect of test day (F(5, 145) = 3.982, P = 0.002),
but no main effect of PCP (F(2,29) = 0.288, P = 0.752), or
PCP × test day interaction (F(10,145) = 1.251, P = 0.264). One-way
ANOVAs did not find any group difference on any test day (all
Ps > 0.453, Figure 5).
3.3. Experiment 3: Effects of repeated quinpirole (0.03–0.12)
or MK-801 (0.025–0.1) treatment on an escalating dose regimen or a constant dose regimen on prepulse inhibition
3.3.1. PPI
As expected, there was no group difference on the averaged percent PPI on the saline day (F(4, 55) = 0.085, P = 0.987, data not
shown). Quinpirole at 0.12 mg/kg disrupted PPI acutely. Analysis
of PPI data from the 6 drug test days revealed a main effect of prepulse level (F(2, 66) = 332.485, P < 0.001) and a significant treatment × test day interaction (F(10, 165) = 2.177, P = 0.022), but no
main effect of treatment (F(2, 33) = 2.424, P = 0.104). These results
suggest that quinpirole disrupted PPI and that the disruption varied in different treatment schedules and across the test days.
At the 73 dB prepulse level (Figure 6A), one-way ANOVA followed by LSD post hoc tests revealed that the QUI-escalating
group had significantly higher PPIs than the other two groups only
on day 4 (all Ps < 0.031). At the 76 dB prepulse intensity level (Figure 6B), the QUI-constant group had a significantly lower PPI
than the vehicle group (P = 0.008) on day 1, indicating an acute
disruptive effect. It also had significantly lower PPIs than the QUIescalating group on day 1 (P = 0.032), day 3 (P = 0.023) and day
4 (P = 0.037). Interestingly, the QUI-escalating group had a significantly higher PPI than the vehicle group on day 4 (P = 0.011).
At the 82 dB prepulse intensity level (Figure 6C), the QUI-constant group had a significantly lower PPI than the vehicle group
(P = 0.043) on day 1. It also had significantly lower PPIs than the
QUI-escalating group on day 1 (P = 0.030), day 2 (P = 0.013), day
3 (P = 0.038) and day 4 (P = 0.015). The QUI-escalating group had
a significantly lower PPI than the vehicle group on the last day of
testing (P = 0.038), when the same dose of QUI in the constant
schedule had no effect (P = 0.146).

Figure 6. Effects of repeated administration of saline (VEH), constant
quinpirole (0.12 mg/kg daily) or escalating quinpirole (0.03–0.12 mg/kg)
for 6 consecutive days on prepulse inhibition (PPI) at the 73 dB (A), 76 dB
(B) and 82 dB (C) prepulse levels. * P < 0.05 significantly different from the
VEH group; # P < 0.05 significantly different between the two quinpirole
groups; $ P < 0.05 significantly different between day 1 and day 6.

In comparison to day 1 of drug testing, only the QUI-escalating group showed a significantly increased disruption of PPI at
the 82 dB level on day 6 (P = 0.035). None of the other groups
showed any significant change (all Ps > 0.065).
For MK-801, repeated measures ANOVA showed a main effect of treatment (F(2, 33) = 17.848, P < 0.001) and prepulse level
(F(2, 66) = 360.912, P < 0.001). There was also a significant treatment × test day interaction (F(10, 165) = 2.605, P = 0.006). These
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results suggest that the disruptive effect of MK-801 on PPI varied under different treatment schedules and differed across the
six test days.
At the 73 dB prepulse intensity level (Figure 7A), one-way
ANOVA followed by LSD post hoc tests revealed that the MK801-constant group had significantly lower PPIs than the vehicle group on every test day (all Ps < 0.030) except on day 4
(P = 0.058). In addition, the MK-801-constant group also had a
significantly lower PPI than the MK-801-escalating group on day
3 (P = 0.006). The MK-801-escalating group had significantly
lower PPIs than the vehicle group on day 1 (P = 0.003) and day
6 (P = 0.023). At the 76 dB prepulse level (Figure 7B), the MK801-constant group had significantly lower PPIs than the vehicle
group on every test day (all Ps < 0.044), whereas the MK-801-escalating group had significantly lower PPIs on days 1, 2, 5 and
6 (all Ps < 0.023). It also had a significantly lower PPI than the
constant group on day 6 (P = 0.012). At the 82 dB prepulse intensity level (Figure 7C), the MK-801-constant group had significantly lower PPIs than the vehicle group on every test day (all
Ps < 0.006). It also had a significantly lower PPI than the escalating group on day 3 (P = 0.042). The MK-801-escalating group had
significantly lower PPIs than the vehicle group on days 2, 4, 5 and
6 (all Ps < 0.032), and significantly lower PPIs than the constant
group on days 5 and 6 (Ps < 0.038).
In comparison to day 1 of drug testing, only the MK-801-escalating group showed a significantly increased disruption of PPI
at the 82 dB level on day 6 (P = 0.014). None of the other groups
showed any significant change (all Ps > 0.060).
3.3.2. Acoustic startle response (ASR)
QUI treatment decreased startle reactivity (Figure 8A). Repeated
measures ANOVAs showed a main effect of treatment (F(2,
33) = 5.366, P = 0.010), a main effect of test day (F(5, 165) = 4.141,
P = 0.001) and a significant treatment × test day interaction
(F(10, 165) = 3.633, P < 0.001). One-way ANOVAs followed by
LSD post hoc test on each test day showed that the QUI-constant group had significantly lower startle amplitude than the
vehicle group on every test day (all Ps < 0.047). The QUI-escalating group had significantly lower startle amplitude than the vehicle group on days 2, 3, 5 and 6 (all Ps < 0.035).
MK-801 treatment increased startle reactivity (Figure 8B).
Repeated measures ANOVAs showed a main effect of treatment (F(2, 33) = 8.527, P = 0.001), a main effect of test day (F(5,
165) = 10.538, P < 0.001) and a significant treatment × test day interaction (F(10, 165) = 8.523, P < 0.001). One-way ANOVAs followed by LSD post hoc test on each test day showed that both
MK-801 groups had significantly higher startle amplitude than
the vehicle group on every test day (all Ps < 0.031) except on day
2 when the MK-801-escalating group did not differ significantly
from the vehicle group (P = 0.368).
4. Discussion
Previous work on the effects of repeated administration of dopamine agonists and NMDA antagonists on PPI has reported either
no change (Druhan et al., 1998; Mansbach et al., 1988; Martinez
et al., 1999; Schwabe et al., 2005), sensitization (Martin-Iverson,
1999; Schulz et al., 2001; Zhang et al., 1998), or tolerance in PPI
(Culm and Hammer, 2004; Feifel et al., 2002) (see (Geyer et al.,
2001; Swerdlow et al., 2008) for detailed tabulations). Besides the
parameter differences in PPI testing, we hypothesized that some
of these differences may be attributable to differences in drug
treatment paradigms, including drug doses, number of drug administrations, routes and treatment schedule, etc. The present
study confirmed this hypothesis regarding dopamine agonists.
For the first time, we showed that when amphetamine 5.0 mg/kg
or quinpirole 0.12 mg/kg was administered in an escalating dosing regimen, both drugs still caused a disruption of PPI on the
test days (days 5 and 6) when the same dose of amphetamine or

Figure 7. Effects of repeated administration of saline (VEH), constant
MK-801 (0.1 mg/kg daily) or escalating MK-801 (0.025–0.10 mg/kg) for 6
consecutive days on prepulse inhibition (PPI) at the 73 dB (A), 76 dB (B)
and 82 dB (C) prepulse levels. * P < 0.05 significantly different from the
VEH group; # P < 0.05 significantly different between the two quinpirole
groups; $ P < 0.05 significantly different between day 1 and day 6.

quinpirole in the constant dosing schedule already lost its effect.
We recently confirmed this general observation in a subsequent
experiment using different doses of amphetamine in the two
schedules. We found that rats that received an escalating amphetamine treatment (days 1–2: 1.0 mg/kg; days 3–4: 2.0 mg/kg,
and days 5–6: 4.0 mg/kg) exhibited PPI deficits on the last 2 days
when they were tested under 4.0 mg/kg amphetamine. However,
this same dose of amphetamine did not disrupt PPI on the last
2 days when it was administered in the constant schedule (days
1–6: 4.0 mg/kg). The consistence of the findings involving different doses of amphetamine suggests the generality of such treatment regimen effect on PPI change.
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Figure 8. Effects of repeated administration of saline (VEH), quinpirole
(0.12 mg/kg daily or 0.03–0.12 mg/kg escalating throughout 6 days) (A) or
MK-801 (or 0.025–0.10 mg/kg escalating throughout 6 days) (B) on startle
reactivity (e.g. startle responses on 120 dB white noise trials). * P < 0.05
significantly different from the VEH group.

The constant dosing of amphetamine and quinpirole tended
to produce a progressively decreased disruption on PPI (a tolerance-like effect). This finding is consistent with earlier studies demonstrating the similar tolerance development associated
with repeated cocaine, amphetamine, quinpirole or apomorphine
treatment (Byrnes and Hammer, 2000; Druhan et al., 1998; Feifel
et al., 2002; Martin-Iverson, 1999). Interestingly, in contrast to the
varying effects of different treatment schedules on PPI, amphetamine or quinpirole administered in both conditions induced a
similar enhanced (a sensitization-like effect for amphetamine)
or decreased (for quinpirole) effect on startle reactivity throughout the treatment days (Figures 3A and 8A), suggesting a dissociation between their PPI effects and effects on startle reactivity, as
they did not occur in parallel. For example, amphetamine 5.0 mg/
kg in the constant dosing schedule caused a significant increase
in startle magnitude on day 6, but it did not disrupt PPI. Conversely, amphetamine 5.0 mg/kg in the escalating dosing schedule did not change startle magnitude on day 6, but it did disrupt
PPI. A similar case could be made for quinpirole. These observations also suggest that the PPI tolerance effect of amphetamine
was not due to a loss of drug action over time, but rather due to
the specific sensitivity of PPI to this drug action. Furthermore, as
rats in the constant dosing groups actually received more amphetamine or quinpirole, these results suggest that the drug dosing
schedule, rather than the absolute amount of drug that an animal
receives plays an important role in the development of PPI-disruptive effect of amphetamine or quinpirole. It suggests that the
brain mechanisms underlying amphetamine-induced change in

PPI disruption may be different from those underlying its sensitization effect on psychomotor function (Druhan et al., 1998). The
dissociation between AMPH-induced PPI disruption and psychomotor sensitization implies that sensitization-like processes and
associated neuroadaptation may not be crucial in the development of a sensorimotor gating deficit as observed in patients with
schizophrenia, although it is required for behavioral sensitization
(Robinson and Becker, 1986).
Our finding that repeated treatment of PCP and MK-801 under the constant and escalating regimens at the tested dose
ranges produced a stable and persistent disruption of PPI is consistent with Martinez et al. (1999) and Schwabe et al. (2005). It is
inconsistent with Schulz et al. (2001), who tested MK-801 in Wistar rats. Thus, this discrepancy could be due to strain-differences
between Wistar and Sprague–Dawley rats (Varty and Higgins,
1995), as the latter is more sensitive to the disruptive effect of
NMDA antagonists. One may suggest that the failure to detect a
sensitization effect might be due to a floor effect in the sense that
PCP and MK-801 at the chosen doses already achieved a maximal PPI disruption. However, the finding that PCP at a low dose
(i.e. 0.5 mg/kg) still failed to induce a consistent increased disruption of PPI (Figure 4) argues against the floor effect explanation. Overall, our results suggest that the PPI disruption induced
by PCP and MK-801 (at the effective dose) is generally quite stable. One caveat is that we only tested relatively low doses of PCP
and MK-801 (< 2.0 mg/kg for PCP and < 0.1 mg/kg for MK-801)
in this study. Other doses of PCP and MK-801 may induce different patterns of PPI disruption under different experimental
conditions.
To the best of our knowledge, there is no published work
that has examined the effects of escalating dose regimen on
PPI throughout the course of drug treatment. Several studies
that have used escalating dosing regimens only tested PPI after
a period of withdrawal from a repeated treatment of amphetamine or PCP. Results are inconsistent. For example, Murphy et
al. (2001a, 2001b) and Russig et al. (2003) reported no PPI disruption in rats treated with an escalating dose of amphetamine,
whereas Tenn et al. (2003, 2005) reported a disruption of PPI in
rats treated with an escalating dose of amphetamine, but not in
rats treated with the same doses of PCP over the same period of
time. Peleg-Raibstein et al. (2006) found that prior AMPH treatment schedule is a critical factor in inducing a long-lasting disruption of PPI. Clinical observations indicate that drug-induced
psychosis is most likely to appear during the course of escalating dosage of drug administration (i.e., “binges” or “runs”), and
discontinuation of drug usage usually results in a rapid decline of the psychosis, closely paralleling urine drug levels (Angrist, 1994; Davis and Schlemmer, 1980). Our finding that an escalating dose of amphetamine produces a sustained disruption
in drug experienced rats seems to capture the emergence of one
important psychological dysfunction (e.g. sensorimotor gating)
identified in patients with schizophrenia very well. This study
thus provides two important paradigms for basic researchers
who are interested in developing animal models that can mimic
the emerging process of sensorimotor gating deficits in patients
with schizophrenia. One option is to use an escalating dosing
regimen with dopamine agonists. The second is to use effective
and low doses of NMDA antagonists such as PCP or MK-801. PPI
disruption induced and maintained under these conditions may
therefore allow us to dissect the neural and neurochemical basis
of symptoms of schizophrenia.
The present study raised an interesting question: Why is an
escalating dosing regimen with amphetamine or quinpirole able
to induce PPI disruption when the same dose of drugs in the
constant schedule is no longer effective? Neurochemical studies have showed that during the course of escalating dose treatment, extracellular dopamine and serotonin levels in the dorsal
and ventral striatum progressively declined (Segal and Kuczenski, 1997), and striatal dopamine release to a challenge amphet-
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amine dose or stress was significantly enhanced, whereas dopamine release remained significantly decreased in the dorsal
medial prefrontal cortex (mPFC) after a certain period of withdrawal (Hedou et al., 2001; Paulson and Robinson, 1995; Tenn et
al., 2003). This suggests that complex, time-dependent neuroadaptations in dopamine systems may lead to persistent PPI disruption under the escalating schedule. Apparently, future work
is needed to elucidate the exact neurochemical mechanisms.
Finally, we should point out that other factors may also influence a drug’s effect on PPI, in addition to the drug administration regimen and PPI parameters. One such factor is whether
drug treatment is paired with the PPI testing environment during the repeated drug treatment period. Since repeated PPI testing involves repeated presentation of startle stimulus which is
a mild stressor by itself, repeated daily testing could conceivably alter drug effects on PPI over time by altering the impacts of
emotional responses (e.g. fear) on PPI performance. In the literature, a tolerance-like or sensitization-like disruption on PPI has
often been found under a condition when the drug injections
were paired with repeated PPI testing (Culm et al., 2004; Feifel
et al., 2002; Martin-Iverson, 1999; Schulz et al., 2001; Zhang et
al., 1998), whereas repeated drug treatment that was not paired
with PPI testing did not result in PPI change (Byrnes and Hammer, 2000; Druhan et al., 1998; Mansbach et al., 1988; Martinez
et al., 1999). It has therefore been suggested that repeated effects of drug treatment on PPI-disruption might be revealed only
in the presence of a drug-associated context (Feifel et al., 2002;
Martin-Iverson, 1999; Russig et al., 2003). Our findings with amphetamine and quinpirole are consistent with this explanation.
This idea fits well with the proposition that psychomotor sensitization is context-specific, and under certain conditions, psychomotor sensitization can only be detected in a specific environment where repeated drug administration occurs (Anagnostaras
and Robinson, 1996; Robinson and Becker, 1986). However, the
impact of this factor may be limited to dopamine agonists because we did not observe any change with NMDA antagonists
(e.g. PCP and MK-801). In light of the evidence that drug-environment pairing is important for the induction of psychomotor
sensitization for dopamine agonists (Anagnostaras and Robinson, 1996), the lack of impact of such a factor on amphetamineinduced PPI change further suggests that the neural basis responsible for amphetamine-induced change in PPI disruption is
likely different from those underlying its psychomotor sensitization (Druhan et al., 1998). Future work should address this issue
further by examining how this factor interacts with other factors
(e.g. PPI testing parameters and drug dosing regimens) in determining the PPI-disruptive effect. This approach will enhance our
ability to develop more reliable animal models based on pharmacological treatment.
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